head JofIMAB
Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2022, vol. 28, issue2
Subject Area: Medicine
-
DOI: 10.5272/jimab.2022282.4356
Published online: 09 May 2022

Review article
J of IMAB. 2022 Apr-Jun;28(2):4356-4360
SERUM PEPSINOGEN I AND PEPSINOGEN II AS NON-INVASIVE BIOMARKERS FOR THE DIAGNOSIS OF CHRONIC ATROPHIC GASTRITIS
Zornica Gorcheva1ORCID logo Corresponding Autoremail, Valeriya Racheva2ORCID logo, Mirela Vasileva3ORCID logo,
1) Clinic of Internal Diseases, St. Marina University Hospital, Medical University, Pleven, Bulgaria.
2) Department of Clinical Laboratory, St. Marina University Hospital, Medical University, Pleven, Bulgaria.
3) Department of Imaging Diagnostic, St. Marina University Hospital, Medical University Pleven, Bulgaria.

ABSTRACT:
Atrophic gastritis, intestinal metaplasia and dysplasia of the gastric mucosa are major risk factors for the development of an intestinal type of gastric cancer. The selection of patients with such lesions could help with early detection and improve better the prognosis. Esophagogastroscopy is the "gold standard" in detecting gastric cancer and precancerous lesions of the stomach. However, this examination is invasive, expensive, and cannot serve as a screening method. Measurement of serum levels of pessinogen I and pessinogen II is used in high-risk populations in Europe and Asia as a non-invasive marker for the diagnosis of chronic atrophic gastritis. A serum pepsinogen I level ≤ 70ng/ml and pepsinogen I/pepsinogen II ratio ≤ 3 are accepted in many countries as values that most accurately identify patients with advanced atrophic gastritis. On the other hand, the differences in the analytical methods used to determine the level of pepsinogens make the interpretation of results and diagnostic validation difficult.

Keywords: pepsinogen, chronic atrophic gastritis, intestinal metaplasia, gastric cancer,

pdf - Download FULL TEXT /PDF 504 KB/
Please cite this article as: Gorcheva Z, Racheva V, Vasileva M. Serum Pepsinogen I and Pepsinogen II as Non-invasive Biomarkers for the Diagnosis of Chronic Atrophic Gastritis. J of IMAB. 2022 Jan-Mar;28(1):4356-4360. DOI: 10.5272/jimab.2022282.4356

Corresponding AutorCorrespondence to: Zornica Gorcheva, Department of Therapeutic Care, Faculty of Heath Care, Medical University Pleven; 25A, Mayor Gortalov str., Pleven, Bulgaria; E-mail: zornica.gorchev@gmail.com

REFERENCES:
1. 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. [PubMed]
2. Bai Y, Li ZS, Zou DW, Wu RP, Yao YZ, Jin ZD, et al. Alarm features and age for predicting upper gastrointestinal malignancy in Chinese patients with dyspepsia with high background prevalence of Helicobacter pylori infection and upper gastrointestinal malignancy: an endoscopic database review of 102,665 patients from 1996 to 2006. Gut. 2010 Jun 1;59(6):722-8. [PubMed]
3.     Quach DT, Vilaichone RK, Vu KV, Yamaoka Y, Sugano K, Mahachai V. Helicobacter pylori Infection and Related Gastrointestinal Diseases in Southeast Asian Countries: An Expert Opinion Survey. Asian Pac J Cancer Prev. 2018 Dec 25;19(12):3565-3569. [PubMed]
4.     Tsukuma H, Oshima A, Narahara H, Morii T. Natural history of early gastric cancer: a non-concurrent, long term, follow up study. Gut. 2000 Nov 1;47(5):618-21. [PubMed]
5.     Cheli R, Simon L, Aste H, Figus IA, Nicolу G, Bajtai A, et al. Atrophic gastritis and intestinal metaplasia in asymptomatic Hungarian and Italian populations. Endoscopy. 1980 Mar 17;12(3):105-8. [PubMed]
6.     Kato I, Tominaga S, Ito Y, Kobayashi S, Yoshii Y, Matsuura A, et al. A Prospective Study of Atrophic Gastritis and Stomach Cancer Risk. Japanese J Cancer Res. 1992 Nov 1;83(11):1137-42. [PubMed]
7. Kato I, Tominaga S, Ito Y, Kobayashi S, Yoshii Y, Matsuura A, Kameya A, Kano T. Atrophic gastritis and stomach cancer risk: cross-sectional analyses. Jpn J Cancer Res. 1992 Oct;83(10):1041-6. [PubMed]
8. Correa P, Piazuelo MB. The gastric precancerous cascade. J Dig Dis. 2012; Jan;13(1):2-9. [PubMed]
9. Correa P. Human Gastric Carcinogenesis: A Multistep and Multifactorial Process- First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992 Dec 15;52(24):6735-40. [PubMed]
10.   Kapadia CR. Gastric atrophy, metaplasia, and dysplasia: A clinical perspective. J Clin Gastroenterol. 2003 May-Jun;36(5 Suppl.):S29-36. [PubMed]
11.   Oliveira C, Pinheiro H, Figueiredo J, Seruca R, Carneiro F. Familial gastric cancer: Genetic susceptibility, pathology, and implications for management. Lancet Oncol. 2015 Feb;16(2):e60-70. [PubMed]
12.   Carneiro F, Machado JC, David L, Reis C, Nogueira AMMF, Sobrinho-Simхes M. Current thoughts on the histopathogenesis of gastric cancer. Eur J Cancer Prev. 2001 Feb;10(1):101-2 [PubMed]
13.   Laurev P. the Two Histological Main Types of Gastric Carcinoma: Diffuse and So-Called Intestinal-Type Carcinoma. an Attempt at a Histo-Clinical Classification. Acta Pathol Microbiol Scand. 1965; 64:31-49. [PubMed]
14. Huang YK, Yu JC, Kang WM, Ma ZQ, Ye X, Tian SB, et al. Significance of serum pepsinogens as a biomarker for gastric cancer and atrophic gastritis screening: A systematic review and meta-analysis. PLoS One. 2015;10(11). [PubMed]
15.   Chen HN, Wang Z, Li X, Zhou ZG. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. Gastric Cancer. 2016 Jan 1;19(1):166-75. [PubMed]
16.   Rugge M, De Boni M, Pennelli G, De Bona M, Giacomelli L, Fassan M, et al. Gastritis OLGA-staging and gastric cancer risk: A twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther. 2010 May;31(10):1104-11. [PubMed]
17.   Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut. 2017 Jan;66(1):6-30. [PubMed]
18.   Broutet N, Plebani M, Sakarovitch C, Sipponen P, Megraud F. Pepsinogen A, pepsinogen C, and gastrin as markers of atrophic chronic gastritis in European dyspeptics. Br J Cancer. 2003 Apr 15;88(8):1239-47. [PubMed]
19.   Samloff IM, Varis K, Ihamaki T, Siurala M, Rotter JI. Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives of patients with pernicious anemia. Gastroenterology. 1982 Jul;83(1 Pt 2):204–9. [PubMed]
20.   Rawla P, Barsouk A. Epidemiology of gastric cancer: Global trends, risk factors and prevention. Prz Gastroenterol. 2019; 14(1):26-38.[PubMed]
21.   Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer. 2006; 9(4):245-53. [PubMed]
22.   Dinis-Ribeiro M, Areia M, De Vries AC, Marcos-Pinto R, Monteiro-Soares M, O'Connor A, et al. Management of precancerous conditions and lesions in the stomach [MAPS]: Guideline from the European Society of Gastrointestinal Endoscopy [ESGE], European Helicobacter Study Group [EHSG], European Society of Pathology [ESP], and the Sociedade Portuguesa de Endoscopia Digestiva [SPED]. Virchows Arch. 2012 Jan;460(1):19-46. [PubMed]
23.   Dinis-Ribeiro M, Yamaki G, Miki K, Costa-Pereira A, Matsukawa M, Kurihara M. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. J Med Screen. 2004; 11(3):141-7. [PubMed]
24.   Ichinose M, Miki K, Furihata C, Kageyama T, Hayashi R, Niwa H, et al. Radioimmunoassay of serum group I and group II pepsinogens in normal controls and patients with various disorders. Clin Chim Acta. 1982 Dec 9;126(2):183-91. [PubMed]
25.   Lomba-Viana R, Dinis-Ribeiro M, Fonseca F, Vieira AS, Bento MJ, Lomba-Viana H. Serum pepsinogen test for early detection of gastric cancer in a European Country. Eur J Gastroenterol Hepatol 2012 Jan;24(1)37-41. [PubMed]
26.   Leja M, Camargo MC, Polaka I, Isajevs S, Liepniece-Karele I, Janciauskas D, et al. Detection of gastric atrophy by circulating pepsinogens: A comparison of three assays. Helicobacter. 2017 Aug 1;22(4):e12393.
27.   Kim EH, Kang H, Park CH, Choi HS, Jung DH, Chung H, et al. The optimal serum pepsinogen cut-off value for predicting histologically confirmed atrophic gastritis. Dig Liver Dis. 2015 Aug;47(8):663-8. [PubMed]
28. Pimentel-Nunes P, Libanio D, Marcos-Pinto R, Areia M, Leja M, Esposito G, et al. Management of epithelial precancerous conditions and lesions in the stomach [MAPS II]: European Society of Gastrointestinal Endoscopy [ESGE], European Helicobacter and Microbiota Study Group [EHMSG], European Society of Pathology [ESP], and Sociedade Port. Endoscopy. 2019 Apr;51(4):365-88. [PubMed]
29. Marcos P, Brito-Gonзalves G, Libвnio D, Pita I, Castro R, Sa I, et al. Endoscopic grading of gastric intestinal metaplasia on risk assessment for early gastric neoplasia: can we replace histology assessment also in the West? Gut. 2020 Oct 1;69(10):1762–8. [PubMed]
30.   Kikuchi S, Kurosawa M, Sakiyama T, Tenjin H, Miki K, Wada O, et al. Long-term effect of Helicobacter pylori infection on serum pepsinogens. Jpn J Cancer Res. 2000 May;91(5):471-6. [PubMed]
31.   Ito M, Haruma K, Kamada T, Mihara M, Kim S, Kitadai Y, et al. Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: A 5-year prospective study of patients with atrophic gastritis. Aliment Pharmacol Ther. 2002 Aug;16(8):1449-56. [PubMed]
32.   Yuan L, Zhao JB, Zhou YL, Qi Y Bin, Guo QY, Zhang HH, et al. Type i and type II Helicobacter pylori infection status and their impact on gastrin and pepsinogen level in a gastric cancer prevalent area. World J Gastroenterol. 2020 Jul 7;26(25):3673-85. [PubMed]
33.   Tu H, Sun L, Dong X, Gong Y, Xu Q, Jing J, et al. Serum anti-Helicobacter pylori immunoglobulin G titer correlates with grade of histological gastritis, mucosal bacterial density, and levels of serum biomarkers. Scand J Gastroenterol. 2014 Mar;49(3):259-66. [PubMed]
34.   Shan JH, Bai XJ, Han LL, Yuan Y, Sun XF. Changes with aging in gastric biomarkers levels and in biochemical factors associated with Helicobacter pylori infection in asymptomatic Chinese population. World J Gastroenterol. 2017 Aug 28;23(32):5945-53. [PubMed]
35.   Tong Y, Wu Y, Song Z, Yu Y, Yu X. The potential value of serum pepsinogen for the diagnosis of atrophic gastritis among the health check-up populations in China: A diagnostic clinical research. BMC Gastroenterol. 2017 Jul 20;17(1):88. [ PubMed]
36.   Huang RG, Xiao HL, Zhou B, Song XH, Zhang J, Wang CM, et al. Serum Pepsinogen Levels Are Correlated With Age, Sex and the Level of Helicobacter pylori Infection in Healthy Individuals. Am J Med Sci. 2016 Nov;352(5):481-6.[ PubMed]
37.   Tong Y, Wang H, Zhao Y, He X, Xu H, Li H, et al. Serum pepsinogen levels in different regions of China and its influencing factors: a multicenter cross-sectional study. BMC Gastroenterol. 2021 Jun 12;21(1):264. [PubMed]
38.   Zhang L, Niu Y, Lv Y-J, Wu L-F, Hu Q-L, Huang R, et al. Preliminary Study on Reference Interval of Serum Pepsinogen in Healthy Subjects. Patient Prefer Adherence. 2021 Dec 9;15:2725-30. [PubMed]

Received: 12 December 2021
Published online: 09 May 2022

back to Online Journal